drugset / Trial / NCT03576001

Multimodality Intervention for Function and Metabolism in SCI

NCT03576001

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The proposed phase 2 trial a randomized, placebo-controlled, parallel group trial in persons with cervical or thoracic SCI, AIS grade A, B, C, or D, 6 months or later after injury. The trial will test the hypothesis that a Home-Based Multimodality Functional Recovery and Metabolic Health Enhancement Program that addresses multiple pathophysiologic factors in SCI and includes functional electrical stimulation during leg cycling (FES-LC) plus arm ergometry and an androgen will be more efficacious than functional electrical stimulation during leg cycling (FES-LC) plus arm ergometry plus placebo in improving aerobic capacity, function, metabolism, bone health, and wellbeing.

Timeline

Start
2019-08-23
Primary completion
2025-01-15
Completion
2025-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule Other

Indications